Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes

被引：0

作者：

Samah Hayek

Yatir Ben-shlomo

Noa Dagan

Ben Y. Reis

Noam Barda

Eldad Kepten

Alina Roitman

Shachar Shapira

Shlomit Yaron

Ran D. Balicer

Doron Netzer

Alon Peretz

机构：

[1] Clalit Health Services,Clalit Research Institute, Innovation Division

[2] Ben Gurion University,Software and Information Systems Engineering

[3] Harvard Medical School,Department of Biomedical Informatics

[4] The Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute,Predictive Medicine Group, Computational Health Informatics Program

[5] Boston Children’s Hospital,Clalit Community Division

[6] Harvard Medical School,Department of Military Medicine, Faculty of Medicine

[7] Clalit Health Services,School of Public Health, Faculty of Health Sciences

[8] Israel Defense Forces Medical Corps,undefined

[9] Hebrew University,undefined

[10] Ben Gurion University of the Negev,undefined

来源：

Nature Communications | / 13卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, has been approved as a treatment for high-risk patients infected with SARS-CoV-2 within five days of their diagnosis. We performed a retrospective cohort study, and used data repositories of Israel’s largest healthcare organization to determine the real-world effectiveness of REGEN-COV treatment against COVID-19-related hospitalization, severe disease, and death. We compared patients infected with Delta variant and treated with REGEN-COV (n = 289) to those infected but not-treated with REGEN-COV (n = 1,296). Demographic and clinical characteristics were used to match patients and for further adjustment as part of the C0x model. Estimated treatment effectiveness was defined as one minus the hazard ratio. Treatment effectiveness of REGEN-COV was 56.4% (95% CI: 23.7–75.1%) in preventing COVID-19 hospitalization, 59.2% (95% CI: 19.9–79.2%) in preventing severe COVID-19, and 93.5% (95% CI: 52.1–99.1%) in preventing COVID-19 death in the 28 days after treatment. In conclusion, REGEN-COV was effective in reducing the risk of severe sequelae in high-risk COVID-19 patients.

引用

共 9 条

[1] Zhu N(2020)A Novel Coronavirus from Patients with Pneumonia in China, 2019 N. Engl. J. Med 382 727-733
[2] Bergwerk M(2021)Covid-19 Breakthrough Infections in Vaccinated Health Care Workers N. Engl. J. Med. 385 1474-1484
[3] Razonable RR(2021)Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19 EClinicalMedicine 40 101102-1090
[4] Gao SJ(2022)Omicron variant (B. 1.1. 529) of SARS‐CoV‐2, a global urgent public health alert! J. Med. Virol. 94 1255-1423
[5] Guo H(2021)Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting N. Engl. J. Med. 385 1078-455
[6] Luo G(2021)BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting N. Engl. J. Med. 384 1412-undefined
[7] Barda N(2021): Risk factors for severe and critically ill COVID‐19 patients: a review Allergy 76 428-undefined
[8] Dagan N(undefined)undefined undefined undefined undefined-undefined
[9] Gao YD(undefined)undefined undefined undefined undefined-undefined

← 1 →